Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics Reports Fourth Quarter and Full Year 2008 Financial Results
March 13th, 2009
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced its financial results for the fourth quarter and full year ended December 31, 2008. “2008 was a year of exceptional achievement for Acorda. Our recent NDA filing for Fampridine-SR in MS follows the success of our second Phase 3 clinical trial, which was conducted under a special protocol assessment from the FDA. We have initiated pre-launch educational programs in the U.S., and are in discussions with potential marketing partners regarding the commercialization of Fampridine-SR in non-U.S. markets,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. “In addition, by the end of this year we plan to file an...
Source: Health Business Week (2009-03-13)
|
